← Back to Search

Platinum-containing compound

Combination Chemotherapy for Lymphoma

Phase 2

Waitlist Available

Research Sponsored by Ottawa Regional Cancer Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Disease has relapsed following or is resistant to primary anthracycline-containing combination chemotherapy

Objective response to salvage DHAP chemotherapy required

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well giving combination chemotherapy consisting of cyclophosphamide, etoposide, and cisplatin works in treating patients with non-Hodgkin's lymphoma.

Who is the study for?

This trial is for adults aged 18-64 with intermediate or high-grade non-Hodgkin's lymphoma that didn't respond to initial anthracycline-based chemo. Participants must have had some positive response to DHAP chemotherapy, be in good physical condition (Zubrod score of 0 or 1), and not have uncontrolled diabetes, other medical conditions, or a history of certain cancers. They should also meet specific blood count and organ function criteria.Check my eligibility

What is being tested?

The study is testing the effectiveness of a combination chemotherapy regimen using cyclophosphamide, etoposide, and cisplatin in patients whose lymphoma has either relapsed after or resisted primary treatment with anthracycline-containing chemo. It's a Phase II trial aimed at seeing how well this new combo works.See study design

What are the potential side effects?

Potential side effects from the drugs used may include nausea, vomiting, hair loss, fatigue, increased risk of infection due to low blood cell counts (neutropenia), kidney damage from cisplatin; heart problems; nerve damage; and infertility.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer came back or didn't respond to my first chemotherapy that included anthracyclines.

Select...

My cancer responded to the last round of DHAP chemotherapy.

Select...

My lymphoma is confirmed to be of a specific type and is not low-grade.

Select...

My liver functions, including bilirubin and SGOT levels, are within normal limits.

Select...

I am between 18 and 64 years old.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

My creatinine level is below 1.5 mg/dl.

Select...

I do not have uncontrolled diabetes or any other unmanaged health issues.

Select...

My heart functions well, with no severe irregular heartbeats or uncontrolled high blood pressure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ottawa Regional Cancer CentreLead Sponsor

6 Previous Clinical Trials

482 Total Patients Enrolled

Jonathan C. Yau, MDStudy ChairOttawa Regional Cancer Centre

Media Library

Cisplatin (Platinum-containing compound) Clinical Trial Eligibility Overview. Trial Name: NCT00002488 — Phase 2

Lymphoma Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT00002488 — Phase 2

Cisplatin (Platinum-containing compound) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002488 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there room for participation in this research endeavor?

"Per information listed on clinicaltrials.gov, this medical trial is no longer accepting patient volunteers. Originally posted in December of 1991 and last updated September 16th 2013, the trial has since been closed for recruitment; however, there are 1,718 other trials open right now."

Answered by AI

What safety parameters have been established for this procedure?

"As this treatment is currently in Phase 2, we assess its safety to be a score of 2. While there are some preliminary studies that demonstrate its safety, no data exists yet supporting the efficacy of this remedy."

Answered by AI